Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393859 | 0.84 | TSHR (0.46) | TSHRTDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL4242291 | 0.83 | KCNA5 (0.64) | KCNA5MAPK1RAB9AKCNK3KCNA3 | |
| SCHEMBL2209712 | 0.82 | KCNA5 (0.74) | KCNA5TSHRKCNK3KCNA3 | |
| SCHEMBL11472039 | 0.82 | SMN1; SMN2 (0.50) | TSHRTDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL2207411 | 0.81 | KCNA5 (0.68) | KCNA5SMN1; SMN2LMNAKCNK3KCNA3 | |
| SCHEMBL15552878 | 0.80 | ACHE (0.51) | TSHRTDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL8802438 | 0.79 | LTB4R2 (0.44) | KCNA5TSHRTDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL11089043 | 0.79 | HPGD (0.51) | TSHRTDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL9368099 | 0.78 | TSHR (0.73) | PTPN11TSHRTDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL2205197 | 0.78 | KCNA5 (0.73) | KCNA5LMNAKCNK3KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-6686395-B2 | THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6531495-B1 | Potassium channel | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | PTPN11 2982/4885KCNA5 104/4885TSHR 680/4885 |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | PTPN11 2933/4885KCNA5 90/4885TSHR 667/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | PTPN11 2946/4885KCNA5 97/4885TSHR 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.